Clinical Trial Update: Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of selinexor (KPT-330), a selective inhibitor of nuclear export, in patients with myelodysplastic syndromes has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2022-03-09